Demographic and Clinicopathologic Risk Factors for Colorectal Polyp Recurrence: A Large-Scale Surveillance Cohort Study

Usman Ayub Awan, PhD[1,2†], Qingyuan Song, PhD[3,4†], Kristen K. Ciombor, MD[5], Adetunji T. Toriola, MD, PhD[6], Jungyoon Choi, MD, PhD[7], Timothy Su, MD, PhD[1], Xiao-ou Shu, PhD[1], Kamran Idrees, MD[8], Kay M. Washington[9], Wei Zheng, MD, PhD[1], Wanqing Wen, MD[1*], Zhijun Yin, PhD[3,4*], Xingyi Guo, PhD[1,3*]

Author Affiliations:

[1] Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA

[2] Department of Medical Laboratory Technology, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan

[3] Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA

[4] Department of Department of Computer Science, Vanderbilt University, Nashville, TN, USA

[5] Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

[6] Division of Public Health Sciences, Department of Surgery, and Siteman Cancer Center, Washington University School of Medicine St. Louis, MO, USA

[7] Division of Oncology and Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

[8] Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center Nashville, TN, USA.

[9] Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee

Key Points: 97 / 100

Abstract: 348 / 350

Text Word Count: 3000/ 3000

Figures & Tables: 05

Supplementary Online Figures & Tables: 04

* Corresponding Authors:
Xingyi Guo, PhD
Vanderbilt University Medical Center
2525 West End Ave, Suite 330
Nashville, Tennessee 37203
Office: 615-936-3471
xingyi.guo@vumc.org

Dr. Zhijun Yin
Vanderbilt University Medical Center
2525 West End Ave. Suite 1475, Nashville, TN 37203
Tel: +1 615-936-3690; Fax: +1 615-322-0102
Email: zhijun.yin.1@vumc.org

Wanqing Wen, MD
Vanderbilt University Medical Center
2525 West End Ave, Suite 334-G, Nashville, 37203
Office: 615-322-0105
wanqing.wen@vumc.org

Running Headline: Investigation of Disparities in Polyp Recurrence Risk

Keywords: Colorectal Polyp Recurrence; Demographic Disparities; Surveillance; Poly Characteristics;
Cohort Study

Key Question

Which demographic and histopathologic factors influence polyp recurrence in post-polypectomy

surveillance, and what are their long-term impacts?

Findings

In a cohort of 68,480 patients, villous histology and high-grade dysplasia were strong predictors

of polyp recurrence. Males and obese patients demonstrated a higher early risk, while non-

Hispanic Black (NHB) patients showed an increased recurrence over time. Both early-onset and

older-onset were protective against recurrence compared to the 51–75 age group.

Meaning

Post-polypectomy surveillance guidelines should incorporate histopathological, demographic,

and obesity, to improve precision and equity in surveillance strategies. Addressing population-

specific risk can optimize long-term outcomes.

Abstract

Importance: Current post-polypectomy surveillance guidelines prioritize polyp characteristics

but insufficiently address demographic disparities and modifiable risk factors, potentially

contributing to inequities in colorectal polyp recurrence.

Objective: To evaluate the association of demographic factors, obesity, and polyp characteristics

with polyp recurrence risk.

Design, Setting, and Participants: This retrospective Polypectomy Cohort study included

68,480 adults undergoing their first polypectomy at a tertiary medical center (January 1990-July

2024), with a median follow-up of 4 years.

Exposures: Risk factors included race/ethnicity (non-Hispanic White [NHW], non-Hispanic

Black [NHB], Hispanic, Asian/Pacific Islander [API]), polyp onset age (≤50, 51–75, ≥76 years),

sex, obesity (BMI >30), and polyp characteristics (size, number, location, histology, dysplasia

grade).

Main Outcomes and Measures: The primary outcome was polyp recurrence-free survival,

defined as the time to recurrence following the initial polypectomy. Cox regression analyses

assessed associations between recurrence and demographic/clinical factors, adjusting for

confounders.

Results: Among 68,480 patients (median age 57.8 years; 50.0% female; 86.6% NHW, 10.5%

NHB), 19,450 (28.4%) experienced recurrence. Males had higher 5-year recurrence risk (aHR,

1.12 [95% CI, 1.08-1.17]; $P = 3.49 \times 10^{\square\square}$) than females, with females showing elevated

villous histology risk (HR, 2.57 [95% CI, 2.26-2.93] vs males 2.42 [95% CI, 2.09-2.8]). NHB

patients had lower 5-year recurrence (24.9% vs 29.1% NHW; aHR, 0.87 [95% CI, 0.81-0.93]; P

$= 2.92 \times 10^{\square\square}$), rising beyond 10 years (aHR, 1.24 [95% CI, 1.06-1.45]; $P = 7.59 \times 10^{\square3}$). Age

≤50 (aHR, 0.87) and ≥76 (aHR, 0.73) was protective vs 51–75. Early-onset polyps were higher

in Hispanic (40.9%) and API (32.7%) vs NHW (26.5%). Villous histology (aHR, 2.40 [95% CI,

2.18-2.65]; $P = 5.26 \times 10^{\square\square\square}$) and high-grade dysplasia (aHR, 2.91 [95% CI, 2.59-3.27]; $P =$

$7.06 \times 10^{\square\square2}$) surpassed polyp size (aHR, 1.65 [95% CI, 1.56-1.75]; $P = 2.15 \times 10^{\square\square3}$) as

recurrence predictors, while obesity elevated early risk (aHR, 1.14 [95% CI, 1.09-1.18]; $P = 5.32$

$\times 10^{-14}$)

Conclusions and Relevance: Demographic factors, histologic features, and obesity are critical

predictors of polyp recurrence. Surveillance guidelines should incorporate histologic risk, obesity

management, and equity-focused strategies to optimize outcomes across diverse populations.

Introduction

Colorectal cancer (CRC) persists as a leading cause of cancer-related mortality globally, with

adenomatous polyps representing the primary precursor lesions for 60–90% of cases [1,2]. While

colonoscopic polypectomy has reduced CRC incidence by 40%-60%, adenoma recurrence

occurs in up to 40% of patients within 3-5 years after the initial polypectomy [1,3]. Current post-

polypectomy surveillance guidelines, such as those from the U.S. Multi-Society Task Force

(USMSTF) and European Society of Gastrointestinal Endoscopy (ESGE), prioritize polyp

characteristics (size, histology, multiplicity) to stratify recurrence risk [1,2]. However, these

guidelines inadequately account for demographic disparities and modifiable risk factors, like

obesity, which may perpetuate inequities in colorectal polyps recurrence and CRC prevention [4-6].

Recent guideline comparisons reveal stark inconsistencies in surveillance recommendations. For

instance, ESGE and British guidelines omit surveillance for 1–4 nonadvanced adenomas,

whereas USMSTF advocates intervals of 3–10 years [1,3,7]. These discrepancies underscore a

broader limitation: guidelines universally neglect demographic variables (race, sex, age) and

obesity. Of note, racial disparities in CRC outcomes reported, non-Hispanic Black (NHB)

individuals experiencing higher CRC incidence and mortality compared to White populations.

However, there are limited studies that have reported for the association between demographic

disparity with adenoma recurrence. Current surveillance protocols fail to integrate race-specific

risk stratification for adenoma recurrence [8,9]. Similarly, central obesity (waist-to-hip ratio) has

recently been shown to confer a 15–18% higher CRC risk per standard deviation increase,

independent of BMI, highlighting visceral adiposity as a stronger predictor than generalized

obesity [5,6]. Furthermore, metabolic syndrome—present in 41.7% of Australian patients with

colorectal neoplasia—doubles the odds of adenoma recurrence yet remains absent from

surveillance protocols [4,6].

Histopathological features such as high-grade dysplasia and villous architecture are recognized
as significant predictors of colorectal adenoma recurrence [9-11]. However, their prioritization in
current clinical guidelines varies, leading to inconsistencies in surveillance recommendations.
For instance, while current frameworks classify high-risk adenomas by polyp count and
advanced histology (e.g., ≥10 mm or high-grade dysplasia), they lack racial variations in
histologic subtype association with adenoma recurrence [9,12]. Compounding this issue, long-term
surveillance data from racially and ethnically diverse populations remain sparse, limiting insights
into disparities in post-polypectomy outcomes [9,13,14].
Studies evaluating risk factors for recurrent colorectal adenoma are often challenging, as they
require long-term data from repeated colonoscopies to confirm recurrence and ensure that
controls receive an "all clear" diagnosis. To overcome this barrier, we recently conducted a large-
scale analysis of Vanderbilt electronic health records (EHRs) (diagnoses, procedures, pathology
reports, etc.) from a large pool of patients (over 3.5 million). Leveraging a comprehensive
dataset of 68,480 individuals from the Polypectomy Cohort, this study aimed to elucidate critical
determinants of post-polypectomy surveillance. By identifying the roles of obesity, demographic
disparities, and polyp characteristics, our findings provide a pivotal role for refining polyp-
centric risk models and establishing targeted surveillance strategies for high-risk populations.
146

Methodology
Study Design and Setting
The Vanderbilt Polypectomy Cohort was recently established to investigate polyp recurrence
patterns across demographic subgroups using clinical data from Vanderbilt University Medical
Center (VUMC) spanning January 1990 through July 2024. To ensure consistency and accuracy
despite changes in clinical practice, diagnostic standards, and coding systems over the years—
including the transition from ICD-9 to ICD-10—harmonized data extraction protocols were
meticulously implemented [15].
Data Source
Data was extracted from VUMC HER system (Epic Systems Corporation's eStar), encompassing
colonoscopy reports, pathology findings, demographics, and comorbidities. To ensure
robustness, a multistep validation process was implemented. First, polyp cases and procedures
were identified using standardized diagnostic and procedural codes (ICD-9, ICD-10, CPT,

HCPCS) to address discrepancies across coding systems. Second, all polyp diagnoses were cross verified against original histopathology reports to confirm neoplastic status, histologic subtype, and dysplasia grade. Third, a secure institutionally managed large language model (LLM) was deployed to extract granular polyp characteristics—including size, number, location, and morphology—from unstructured clinical notes and pathology reports, with a verification rate > 95% based on our comparison between procedural codes and LLM from randomly selected 100 patient records [16].

Vanderbilt Polypectomy Cohort Identification

The study population comprised adults aged ≥18 years with histopathologically confirmed colorectal polyps who underwent polypectomy at VUMC. Exclusion criteria were prior CRC and other cancers, colectomy, or incomplete colonoscopies. Colorectal adenomas were categorized as high-risk if they met one or more criteria: ≥3 polyps, size ≥10 mm, villous/tubulovillous histology, or high-grade dysplasia. Low-risk adenomas were defined as <3 Polyps, <10 mm in size, and low-grade dysplasia. A multidisciplinary team (U.A.A., Q.S., Z.Y., X.G.) independently reviewed cohort eligibility to ensure adherence to clinical and histopathologic standards.

Data Extraction and Variable Definitions

Variables were extracted and categorized as follows: Demographic factors included age (stratified as ≤50, 51–75, ≥76 years), sex (male/female), and self-reported race/ethnicity (non-Hispanic White [NHW], NHB, Hispanic, Asian/Pacific Islander [API]). Clinical variables included obesity (BMI ≥30 kg/m², defined via ICD-9/ICD-10 codes), medication use (e.g., aspirin, NSAIDs) and screening colonoscopies (procedures without biopsy). Polyp characteristics encompassed histologic subtype (tubular, tubulovillous, villous, serrated, mixed, non-neoplastic), polyp number (<3 vs. ≥3), size (<10 mm vs. ≥10 mm), dysplasia grade (low/high), and location. The primary outcome, recurrence-free survival, was defined as the time from initial polypectomy to histologically confirmed recurrence on subsequent colonoscopy (≥6 months post-procedure). For analysis of polyp onset age, patients were categorized into three groups: Early Polyp Onset (≤50 years), Intermediate polyp Onset (51-75 years), and Late Onset (≥76 years).

Furthermore, a secure LLM managed by VUMC was used to extract polyp characteristics—including type, number, and size—from unstructured histopathology reports and clinical notes. The LLM utilized case-insensitive keyword searches to identify relevant terms such

as *polypectomy*, *adenoma*, *tubul*, *villous*, *sessile*, *plastic*, and *serrated* within clinical documentation (Supplement 1). Variables with incomplete or unextractable data (e.g., missing histology, size, or multiplicity) were systematically labeled as *Not Defined* to preserve data integrity and transparency.

Follow-Up and Censoring

Patients were followed from the index polypectomy until the earliest occurrence of polyp recurrence, death, loss to follow-up, or the study's end in July 2024. Longitudinal recurrence patterns were primarily evaluated using a 5-year follow-up interval, with events after this period censored, while additional intervals of <5 years, 5-10 years, and >10 years were assessed to explore trends, as detailed in the supplementary files (eTable 1, 2), censoring events after 5 years for the <5-year analysis, after 10 years for the 5-10-year analysis, and analyzing events beyond 10 years for the >10-year interval. Patients undergoing colectomy (complete or partial) or lost to follow-up were censored at their last documented clinical contact.

Statistical Analysis

Baseline characteristics were summarized using descriptive statistics, with categorical variables reported as numbers and percentages (%). Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for potential confounders including race/ethnicity, sex, obesity, NSAID, Aspirin use (during the post-polypectomy period) and polyp characteristics (number, size, and type), and baseline adenoma risk (high vs low). Recurrence patterns were primarily assessed using a 5-year follow-up interval, with extended intervals up to and beyond 10 years evaluated to explore long-term trends, censoring events after each interval as appropriate. The proportional hazards assumption was verified using Schoenfeld residuals, and survival curves were generated via the Kaplan-Meier method to compare recurrence-free probabilities across demographic and clinical subgroups. Stratified analyses were conducted by race/ethnicity, sex, recurrence status, and follow-up interval (5- vs. 10-year windows). Statistical significance was defined as a two-tailed $P < 0.05$.

Ethical Considerations

This study was reviewed and exempted from human subjects' research by the Institutional Review Board at Vanderbilt University Medical Center (IRB #250158). Patient confidentiality was maintained through data de-identification, and all procedures adhered to relevant ethical standards. Data was stored and analyzed in a secure, encrypted, access-controlled database.

Results

The Polypectomy Cohort comprised 68,480 patients who underwent colon polypectomy and were followed up to 25 years (Figure 1). Significant variations in recurrence and survival were observed across demographic and clinical subgroups. The cohort was evenly distributed by sex (34,268 women [50.0%] and 34,212 men [50.0%]) and predominantly NHW (59,339 [86.6%]), with NHB (7,213 [10.5%]), API (1,182 [1.7%]), and Hispanic (746 [1.1%]) participants (Table 1). Age distribution was concentrated in the 51- to 75-year range (46,564 [68.0%]), with smaller proportions aged 50 years or younger (18,550 [27.1%]) and 76 years or older (3,366 [4.9%]).

Polyp Distribution by Subgroups

Polyp characteristics varied significantly by sex and race/ethnicity (Table 1). Males had higher rates of tubulovillous adenomas (1,293 [3.8%] vs 1,056 [3.1%] in females) and mixed adenomas (8,450 [24.7%] vs 8,005 [23.4%] in females), while females had more serrated adenomas (1,730 [5.0%] vs 1,014 [3.0%] in males) and villous adenomas (1,033 [3.0%] vs 670 [2.0%] in males) ($P < .001$). Males also had more multiple polyps ($\geq$3: 4,520 [13.2%] vs 3,783 [11.0%] in females; $P < .001$). Racially, NHW patients had higher rates of mixed adenomas (14,400 [24.3%]) and serrated adenomas (2,485 [4.2%]), NHB had more non-neoplastic adenomas (1,241 [17.2%]) and tubulovillous adenomas (325 [4.5%]), and API had the highest tubular adenoma prevalence (403 [34.1%]) ($P < .001$). Early-onset polyps ($\leq$50 years) were more common in API (387 [32.7%]) and Hispanic patients (305 [40.9%]) than in NHW (15,721 [26.5%]; $P < .001$).

Recurrence Rates and Demographic-Clinical Risk Factors

Polyp recurrence occurred in 28.4% (19,450) of patients within 5 years (Table 2). Males had a higher recurrence rate than females (30.0% vs 26.8%; aHR, 1.12 [95% CI, 1.08-1.17]; $P = 3.49 \times 10^{\square\square}$), though females showed greater risk with specific polyp types, such as tubulovillous histology (HR 2.17 [95% CI, 1.9-2.49] vs males HR 1.79 [95% CI, 1.58-2.02]) and large polyps ($\geq$10 mm: HR 1.62 [95% CI, 1.49-1.77] vs males HR 1.42 [95% CI, 1.31-1.54]; eTable 4). NHW patients had a 29.1% recurrence rate, compared to 24.9% in NHB (aHR, 0.87 [95% CI, 0.81-0.93]; $P = 2.92 \times 10^{\square\square}$), 24.0% in API (aHR, 0.75 [95% CI, 0.63-0.89]; $P = 1.24 \times 10^{\square 3}$), and 16.5% in Hispanic patients (aHR, 0.91 [95% CI, 0.72-1.15]; $P = 4.32 \times 10^{\square 1}$).

NHB patients had higher risks with high-grade dysplasia (HR 2.85 [95% CI, 2.07-3.94] vs NHW HR 2.27 [95% CI, 2.0-2.58]) and multiple polyps (≥3: HR 1.66 [95% CI, 1.41-1.95] vs NHW HR 1.54 [95% CI, 1.46-1.63]; eTable 3). Sex-specific risks and ethnic-specific polyp risks further delineated these patterns (eTable 3, 4).

Age influenced recurrence, with the 51–75-year group (30.0%) as reference: patients ≤50 years had a 27.4% rate (aHR, 0.87 [95% CI, 0.80-0.95]; $P = 8.90 \times 10^{\square\square}$), and those ≥76 years had 12.4% (aHR, 0.73 [95% CI, 0.65-0.83]; $P = 4.78 \times 10^{\square\square}$). Obesity increased recurrence risk (31.0% vs 69.0% overall cohort rate; aHR, 1.14 [95% CI, 1.09-1.18]; $P = 5.32 \times 10^{\square 1 \square}$).

Histopathological features were the strongest predictors (Table 3). Villous histology had a 57.7% recurrence rate (aHR, 2.40 [95% CI, 2.18-2.65]; $P = 5.26 \times 10^{\square\square\square}$), high-grade dysplasia had an aHR of 2.91 [95% CI, 2.59-3.27]; $P = 7.06 \times 10^{\square\square 2}$, and high-risk adenomas (≥3 polyps, ≥10 mm, villous/tubulovillous, or high-grade dysplasia) had an aHR of 2.75 [95% CI, 2.64-2.86]; $P = 2.2 \times 10^{\square 1 \square}$. Polyp size ≥10 mm increased risk (aHR, 1.65 [95% CI, 1.56-1.75]; $P = 2.15 \times 10^{\square\square 3}$); however, less than histology. These differences in recurrence-free survival are illustrated in Figure 2, which presents adjusted survival curves for polyp type, dysplasia grade, number of polyps, and polyp size over a 5-year period.

Long-Term Outcomes and Survival Analysis

Recurrence risk evolved over 25 years, with histopathological features remaining the strongest predictors (eTable 1, eTable 2). Villous histology sustained a high risk beyond 10 years (aHR 2.28 [95% CI, 1.83-2.83]), and high-grade dysplasia, though declining, persisted as a significant factor (5-10 years: aHR 0.68 [95% CI, 0.49-0.95]; >10 years: aHR 0.57 [95% CI, 0.28-1.16]). Multiple polyps (≥3) showed a diminishing effect (5-10 years: aHR 1.05 [95% CI, 0.96-1.14]; >10 years: aHR 0.89 [95% CI, 0.73-1.08]). Male risk moderated over time (5-10 years: aHR 1.17 [95% CI, 1.06-1.29]; >10 years: aHR 1.11 [95% CI, 0.97-1.27]), while NHB risk shifted from protective (5-10 years: aHR 0.95 [95% CI, 0.86-1.06]) to elevated (>10 years: aHR 1.24 [95% CI, 1.06-1.45]). Late-onset polyps (≥76 years) consistently reduced risk (5-10 years: aHR 0.43 [95% CI, 0.32-0.56]), and obesity's influence waned (5-10 years: aHR 0.97 [95% CI, 0.91-1.04]; >10 years: aHR 1.13 [95% CI, 1.02-1.25]).

Discussion

Our Vanderbilt Polypectomy Cohort, encompassing 68,480 patients who underwent polypectomy, provides critical insights into the demographic and clinicopathological factors driving colorectal polyp recurrence and long-term outcomes. This study reveals distinct recurrence patterns across sex, age, race, and histopathological subtypes, offering opportunities to refine current post-polypectomy surveillance guidelines, such as those from the USMSTF and ESGE, and to develop personalized risk stratification strategies.

Males exhibited a higher recurrence rate (10,253 [30.0%] vs 9,197 [26.8%] in females; aHR, 1.12 [95% CI, 1.08-1.17]; $P = 3.49 \times 10^{\square\square}$) and greater prevalence of tubulovillous (1,293 [3.8%] vs 1,056 [3.1%] in females) and mixed adenomas (8,450 [24.7%] vs 8,005 [23.4%] in females), aligning with studies linking male sex to increased polyp prevalence[17-20]. . Yet, females showed elevated recurrence risks with tubulovillous histology (HR, 2.17 [95% CI, 1.9-2.49]; $P = 3.29 \times 10^{\square 2\square}$ vs males HR, 1.79 [95% CI, 1.58-2.02]; $P = 5.54 \times 10^{\square 2\square}$) and large polyps (≥10 mm: HR, 1.62 [95% CI, 1.49-1.77] vs males HR, 1.42 [95% CI, 1.31-1.54]; eTable 4). This sex-histology interaction indicates that the USMSTF's uniform 3–10-year surveillance intervals[9] may overlook female-specific risks, suggesting sex-stratified intervals to enhance precision and equity in guidelines.

Racial variations in polyp profiles revealed significant disparities, with NHB patients showing higher proportions of tubulovillous adenomas (325 [4.5%] vs 1,972 [3.3%] in NHW) and non-neoplastic polyps (1,241 [17.2%] vs 7,297 [12.3%] in NHW), while API patients exhibited the highest tubular adenoma prevalence (403 [34.1%] vs 14,844 [25.0%] in NHW). Early-onset polyps (≤50 years) were more frequent in Hispanic (305 [40.9%]) and API patients (387 [32.7%]) than in NHW (15,721 [26.5%]; $P = 1.2 \times 10^{\square 2\square}$), suggesting the improvement for the USMSTF's uniform screening age of 45 years[36,37]. At 5 years, NHW patients had a higher recurrence rate (17,248 [29.1%] vs 1,795 [24.9%] in NHB; aHR, 0.87 [95% CI, 0.81-0.93]; $P = 2.92 \times 10^{\square\square}$), driven by greater serrated polyp prevalence (2,485 [4.2%] vs 191 [2.6%]; <5 years HR, 1.31 [95% CI, 1.19-1.45]; $P = 5.42 \times 10^{\square\square}$; eTable 2), more high-risk adenomas (13,820 [23.3%] vs 1,723 [23.9%]; <5 years HR, 2.75 [95% CI, 2.64-2.86]; $P = 2.2 \times 10^{\square 1\square}$; eTable 2), and villous histology (1,523 [2.6%] vs 149 [2.1%]; <5 years HR, 2.40 [95% CI, 2.18-2.65]; $P = 5.26 \times 10^{\square\square\square}$; eTable 2). Conversely, NHB risk rose beyond 10 years (aHR, 1.24 [95% CI, 1.06-1.45]; $P = 7.59 \times 10^{\square 3}$; eTable 1), with elevated 5-year recurrence from tubulovillous histology (HR, 2.26 [95% CI, 1.61-3.15]; $P = 1.99 \times 10^{\square\square}$ vs NHW HR,

2.52 [95% CI, 2.26-2.8]; $P = 5.32 \times 10^{\square\square}$) and high-grade dysplasia (HR, 2.85 [95% CI, 2.07-3.94]; $P = 1.81 \times 10^{\square 1\square}$ vs NHW HR, 2.27 [95% CI, 2.0-2.58]; $P = 9.12 \times 10^{\square 3\square}$; eTable 3). These time-stratified racial and histologic patterns suggest that USMSTF/ESGE guidelines[236,37], lacking race-specific and dynamic intervals, underestimate NHB's long-term risk and miss early-onset disparities in Hispanic/API groups, supporting tailored screening and surveillance strategies.

Multiple factors may underline the observed racial disparities in polyp recurrence. Although our analysis adjusted for age, obesity, polyp characteristics, and histology, residual confounding from unmeasured variables—such as healthcare access inequalities, screening underutilization, and later-stage presentation[21-23]. Prior studies attribute CRC disparities in NHB adults to later-stage presentation, unequal healthcare access, and lower screening rates [45,49]. In contrast to previous studies[24-28], our cohort showed a lower 5-year recurrence rate in NHB (1,795 [24.9%] vs 17,248 [29.1%] in NHW; aHR, 0.87 [95% CI, 0.81-0.93]; $P = 2.92 \times 10^{\square\square}$), despite higher tubulovillous (325 [4.5%] vs 1,972 [3.3%]) and non-neoplastic polyp prevalence (1,241 [17.2%] vs 7,297 [12.3%]). Intensive surveillance in our engaged cohort may offset some inequities if NHB patients received equal or greater colonoscopy follow-up, though NHW's higher early recurrence reflects a larger serrated polyp burden (2,485 [4.2%] vs 191 [2.6%]; <5 years HR, 1.31 [95% CI, 1.19-1.45]; $P = 5.42 \times 10^{\square\square}$; eTable 2). Studies by Kwah et al,[29] Martinez et al,[30] and Laiyemo et al[31] also found no significant racial differences in advanced neoplasia prevalence or recurrence, suggesting that surveillance intensity or polyp characteristics may influence our observed disparity. However, current guidelines[236,37], focusing solely on polyp characteristics without racial or temporal adjustments, fail to address these dynamic patterns. Incorporating race-specific social and biological factors into surveillance strategies could enhance equity and precision across diverse populations.

Obesity, present in 22,842 patients (33.4%) of our cohort, was a significant predictor of polyp recurrence (aHR, 1.14 [95% CI, 1.09-1.18]; $P = 5.32 \times 10^{\square 1\square}$). Its impact was particularly pronounced among females, who exhibited a higher obesity prevalence (12,324 [36%] vs 10,518 [30.7%] in males), suggesting a sex-obesity interaction that may amplify recurrence risk. These findings align with prior studies, for instance, Jung *et al.*[32] found that higher baseline BMI categories increased the risk of advanced adenoma, while the central obesity (waist circumference ≥85 cm in men, ≥82 cm in women) was linked to a 31% increased

risk of metachronous adenomas, emphasizing the role of visceral adiposity in promoting

aggressive polyp biology[33]. The association between demographic and modifiable risk factors

suggests a role for targeted interventions, with obesity-related mechanisms (e.g., pro-

inflammatory cytokines, insulin resistance, adipose-derived growth factors) potentially

amplifying polyp recurrence risk [34,35].

Villous adenomas strongly predicted polyp recurrence (aHR, 2.40 [95% CI, 2.18-2.65]; P

$= 5.26 \times 10^{\square\square\square}$), with sustained risk beyond 10 years (HR, 2.28 [95% CI, 1.83-2.83]; $P = 1.40$

$\times 10^{\square 13}$; eTable 2), reflecting their malignant potential due to complex glandular architecture.

High-grade dysplasia also increased recurrence (aHR, 2.91 [95% CI, 2.59-3.27]; $P = 7.06 \times$

$10^{\square\square 2}$), peaking early (<5 years) but waning long-term (>10 years HR, 0.57 [95% CI, 0.28-

1.16]; $P = 1.24 \times 10^{\square 1}$; eTable 2), with a pronounced sex-histology interaction in females with

villous features and large polyps (≥10 mm: HR, 2.57 [95% CI, 2.26-2.93]; $P = 3.63 \times 10^{\square\square\square}$ vs

males HR, 2.42 [95% CI, 2.09-2.8]; $P = 1.19 \times 10^{\square 32}$; eTable 4). This finding aligns with the

USMSTF guidelines[36,37], which classify villous histology and high-grade dysplasia as high-risk

features warranting a 3-year surveillance interval, but contrasts with ESGE guidelines[2], which

prioritize size and dysplasia over villous histology alone. A recent study identified high-risk

pathology, such as dysplasia, as a critical predictor of advanced adenoma recurrence (OR,

6.33)[38], supporting the need for histology-focused surveillance strategies.

This study offers several strengths that advance the understanding of colorectal polyp

recurrence following polypectomy. First, its large cohort size and extended follow-up duration

surpass those of prior studies, providing robust statistical power to examine long-term recurrence

patterns across diverse populations. Second, the comprehensive assessment of demographic

variables and histopathological features enabled the identification of novel interactions,

enhancing the understanding of recurrence risk beyond traditional polyp characteristics. Third,

the incorporation of time-dependent analyses offers a longitudinal perspective rarely explored in

existing research, providing critical insights into the temporal dynamics of recurrence risk. These

findings address gaps in USMSTF guidelines, which lack demographic stratification, and inform

targeted prevention strategies for high-risk groups. However, several important limitations must

be considered. As a single-center study with a predominantly NHW population (87%), our

results may not be fully generalizable to other settings. Its retrospective design risks selection

bias and residual confounding from unmeasured variables (e.g., lifestyle, socioeconomic factors).

Despite these limitations, the large sample size and extended follow-up provide valuable insights, and multi-center studies with diverse populations are needed to further validate our findings in the future.

Conclusion

This cohort study identified polyp recurrence patterns that propose refinements to current surveillance approaches. Histopathological features like villous histology and high-grade dysplasia emerged as key predictors, with villous risk persisting over time and showing greater impact in females. Males and obese patients exhibited elevated early risks, while NHB patients had lower initial recurrence than anticipated, later transitioning to higher risk. Early-onset polyps were more common in Hispanic and API populations, suggesting demographic variations. These time- and sex-stratified insights indicate that current guidelines, currently focused on polyp characteristics alone, may benefit from integrating demographic and dynamic risk factors to improve precision and equity in surveillance across diverse groups.

References:

1. Jung YS. Summary and comparison of recently updated post-polypectomy surveillance guidelines. *Intestinal research.* 2023;21(4):443-451.
2. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. *Endoscopy.* 2020;52(8):687-700.
3. Abu-Freha N, Katz LH, Kariv R, et al. Post-polypectomy surveillance colonoscopy: Comparison of the updated guidelines. *United European gastroenterology journal.* 2021;9(6):681-687.
4. Kumar R, Brown A, Okano S, et al. Overweight and obesity are associated with colorectal neoplasia in an Australian outpatient population. *Scientific Reports.* 2024;14(1):23501.
5. Safizadeh F, Mandic M, Schöttker B, Hoffmeister M, Brenner H. Central obesity may account for most of the colorectal cancer risk linked to obesity: evidence from the UK Biobank prospective cohort. *International Journal of Obesity.* 2024:1-8.
6. Zhang X, Xu Z, Shang L, et al. Global burden of colorectal cancer attributable to metabolic risks from 1990 to 2021, with predictions to 2046. *BMC cancer.* 2025;25(1):228.
7. He X, Hang D, Wu K, et al. Long-term risk of colorectal cancer after removal of conventional adenomas and serrated polyps. *Gastroenterology.* 2020;158(4):852-861. e854.

8.   McLeod MR, Galoosian A, May FP. Racial and Ethnic Disparities in Colorectal Cancer
Screening and Outcomes. *Hematology/oncology clinics of North America.*
2022;36(3):415-428.
9.   Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after
colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force
on Colorectal Cancer. *Official journal of the American College of Gastroenterology|*
ACG. 2020;115(3):415-434.
10.   Hassan C, Antonelli G, Dumonceau J-M, et al. Post-polypectomy colonoscopy
surveillance: European society of gastrointestinal endoscopy (ESGE) guideline–update
2020. *Endoscopy.* 2020;52(08):687-700.
11.   Rutter MD, East J, Rees CJ, et al. British Society of Gastroenterology/Association of
Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy
and post-colorectal cancer resection surveillance guidelines. *Gut.* 2020;69(2):201-223.
12.   Rutter MD, East J, Rees C, Cripps N, Docherty J, Dolwani S. BSG/ACPGBI/PHE Post-
polypectomy and post-colorectal cancer resection surveillance guidelines. *Gut.*
2020;2020:201-223.
13.   Kamal Y, Idos G. Incidental Young-Onset Adenomas: Sporadic Findings or Harbingers of
Increased Colon Cancer Risk? *Current Treatment Options in Gastroenterology.*
2022;20(2):122-132.
14.   Issaka RB, Chan AT, Gupta S. AGA clinical practice update on risk stratification for
colorectal cancer screening and post-polypectomy surveillance: expert review.
Gastroenterology. 2023.
15.   Indicators AQ. ICD-9-CM to ICD-10-CM/PCS Conversion of AHRQ Quality Indicators.
2011. https://qualityindicators.ahrq.gov/Downloads/Resources/Publications/2011/ICD-
10_Report_02-08-11_Final.pdf. Accessed 02-15-2025.
16.   Huang J, Yang DM, Rong R, et al. A critical assessment of using ChatGPT for extracting
structured data from clinical notes. *npj Digital Medicine.* 2024;7(1):106.
17.   Calderwood AH, Tosteson TD, Walter LC, Hua *P*, Onega T. Colonoscopy utilization and
outcomes in older adults: Data from the New Hampshire Colonoscopy Registry. *J Am*
Geriatr Soc. 2022;70(3):801-811.
18.   Penn E, Garrow D, Romagnuolo J. Influence of race and sex on prevalence and
recurrence of colon polyps. *Archives of internal medicine.* 2010;170(13):1127-1132.
19.   Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas,
advanced adenomas, and colorectal cancer in individuals undergoing screening
colonoscopy. *Jama.* 2011;306(12):1352-1358.
20.   Hao Y, Wang Y, Qi M, He X, Zhu Y, Hong J. Risk factors for recurrent colorectal polyps.
Gut and Liver. 2019;14(4):399.
21.   McLeod MR, Galoosian A, May FP. Racial and ethnic disparities in colorectal cancer
screening and outcomes. *Hematology/Oncology Clinics.* 2022;36(3):415-428.
22.   White PM, Itzkowitz SH. Barriers driving racial disparities in colorectal cancer screening
in African Americans. *Current Gastroenterology Reports.* 2020;22:1-7.
23.   O'Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal
cancer: a systematic review and meta-analysis. *Clinical gastroenterology and hepatology.*
2022;20(6):1229-1240. e1225.

24.   Rutter CM, Knudsen AB, Lin JS, Bouskill KE. Black and white differences in colorectal
cancer screening and screening outcomes: a narrative review. *Cancer Epidemiology,*
Biomarkers & Prevention. 2021;30(1):3-12.
25.   Kim RB, Zhou E, Swinnerton KN, et al. Racial and Ethnic Disparity for Cancer Mortality
in General and Single-Payer Healthcare Systems in the United States. *Journal of Racial*
and Ethnic Health Disparities. 2024:1-9.
26.   Lieberman DA, Holub JL, Moravec MD, Eisen GM, Peters D, Morris CD. Prevalence of
colon polyps detected by colonoscopy screening in asymptomatic black and white
patients. *Jama.* 2008;300(12):1417-1422.
27.   Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US
Preventive Services Task Force recommendation statement. *Jama.* 2021;325(19):1965-
1977.
28.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA: a cancer journal for*
clinicians. 2018;68(1):7-30.
29.   Kwah J, Schroy PC, Jacobson BC, Calderwood AH. Whites and blacks have similar risk
of metachronous advanced colorectal neoplasia. *Digestive diseases and sciences.*
2014;59:2264-2271.
30.   Martínez ME, Baron JA, Lieberman DA, et al. A pooled analysis of advanced colorectal
neoplasia diagnoses after colonoscopic polypectomy. *Gastroenterology.* 2009;136(3):832-
841.
31.   Laiyemo AO, Doubeni C, Brim H, et al. Short- and long-term risk of colorectal adenoma
recurrence among whites and blacks. *Gastrointest Endosc.* 2013;77(3):447-454.
32.   Jung YS, Park JH, Park DI, Sohn CI, Choi K. Weight Change and Obesity Are Associated
with a Risk of Adenoma Recurrence. *Dig Dis Sci.* 2016;61(9):2694-2703.
33.   Kim TJ, Kim JE, Choi YH, et al. Obesity-related parameters and colorectal adenoma
development. *Journal of gastroenterology.* 2017;52(12):1221-1229.
34.   Park J, Kim JH, Lee HJ, et al. The effects of physical activity and body fat mass on
colorectal polyp recurrence in patients with previous colorectal cancer. *Cancer*
Prevention Research. 2017;10(8):478-484.
35.   Hussan H, Ali MR, Hussain SK, et al. The impact of surgical weight loss procedures on
the risk of metachronous colorectal neoplasia: the differential effect of surgery type, sex,
and anatomic location. *JNCI Monographs.* 2023;2023(61):77-83.
36.   Gupta S, Lieberman D, Anderson JC, et al. Recommendations for Follow-Up After
Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force
on Colorectal Cancer. *Gastroenterology.* 2020;158(4):1131-1153.e1135.
37.   Shaukat A, Kaltenbach T, Dominitz JA, et al. Endoscopic Recognition and Management
Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society
Task Force on Colorectal Cancer. *Gastroenterology.* 2020;159(5):1916-1934.e1912.
38.   Zhang J, Deng Y, Tang H, et al. New predictors of recurrence in post-polypectomy
surveillance: a retrospective analysis of risk stratification for advanced adenomas and
polyps. *Revista espanola de enfermedades digestivas.* 2024.
497

Table 1: Baseline Characteristics of the Study Population Stratified by Race/Ethnicity and Sex.

Variable	N = 68,480[1]	Ethnicity					Gender		
		Asian or Pacific Islander	Hispanic	Non-Hispanic Black	Non-Hispanic White	p-value[2]	Female	Male	p-value[2]
		N = 1,182[1]	N = 746[1]	N = 7,213[1]	N = 59,339[1]		N = 34,268[1]	N = 34,212[1]	
Demographics Characteristics									
Gender						1.4×10^{-1}			
Female	34,268 (50.0%)	585 (49.5%)	406 (54.4%)	4,219 (58.5%)	29,058 (49.0%)		-	-	
Male	34,212 (50.0%)	597 (50.5%)	340 (45.6%)	2,994 (41.5%)	30,281 (51.0%)		-	-	
Obesity	22,842 (33.4%)	145 (12.3%)	246 (33.0%)	3,458 (47.9%)	18,993 (32.0%)	4.1×10^{-211}	12,324 (36.0%)	10,518 (30.7%)	$1.5 \times 10^{-}$
Polyp Onset Age (yrs)						1.2×10^{-2}			$1.3 \times 10^{-}$
≤50	18,550 (27.1%)	387 (32.7%)	305 (40.9%)	2,137 (29.6%)	15,721 (26.5%)		9,632 (28.1%)	8,918 (26.1%)	
51-75	46,564 (68.0%)	749 (63.4%)	423 (56.7%)	4,796 (66.5%)	40,596 (68.4%)		22,962 (67.0%)	23,602 (69.0%)	
≥ 76	3,366 (4.9%)	46 (3.9%)	18 (2.4%)	280 (3.9%)	3,022 (5.1%)		1,674 (4.9%)	1,692 (4.9%)	
Polyp Characteristics									
Polyp Type						1.4×10^{-1}			5.3×10^{-2}
Mixed	16,455 (24.0%)	255 (21.6%)	156 (20.9%)	1,644 (22.8%)	14,400 (24.3%)		8,005 (23.4%)	8,450 (24.7%)	
Non-neoplastic	8,813 (12.9%)	175 (14.8%)	100 (13.4%)	1,241 (17.2%)	7,297 (12.3%)		4,867 (14.2%)	3,946 (11.5%)	
Not defined	18,750 (27.4%)	260 (22.0%)	177 (23.7%)	1,495 (20.7%)	16,818 (28.3%)		9,018 (26.3%)	9,732 (28.4%)	
Serrated	2,744 (4.0%)	42 (3.6%)	26 (3.5%)	191 (2.6%)	2,485 (4.2%)		1,730 (5.0%)	1,014 (3.0%)	
Tubular	17,666 (25.8%)	403 (34.1%)	251 (33.6%)	2,168 (30.1%)	14,844 (25.0%)		8,559 (25.0%)	9,107 (26.6%)	
Tubulovillous	2,349 (3.4%)	28 (2.4%)	24 (3.2%)	325 (4.5%)	1,972 (3.3%)		1,056 (3.1%)	1,293 (3.8%)	
Villous	1,703 (2.5%)	19 (1.6%)	12 (1.6%)	149 (2.1%)	1,523 (2.6%)		1,033 (3.0%)	670 (2.0%)	
Dysplasia						0.15			$3.4 \times 10^{-}$
High grade	1,141 (1.7%)	19 (1.6%)	16 (2.1%)	141 (2.0%)	965 (1.6%)		511 (1.5%)	630 (1.8%)	
Low grade	67,339 (98.3%)	1,163 (98.4%)	730 (97.9%)	7,072 (98.0%)	58,374 (98.4%)		33,757 (98.5%)	33,582 (98.2%)	
Number of Polyp						3.7×10^{-11}			7.0×10^{-1}

Variable						p-value			p-value
<3	43,867 (64.1%)	869 (73.5%)	509 (68.2%)	5,346 (74.1%)	37,143 (62.6%)		22,792 (66.5%)	21,075 (61.6%)	
≥3	8,303 (12.1%)	133 (11.3%)	99 (13.3%)	873 (12.1%)	7,198 (12.1%)		3,783 (11.0%)	4,520 (13.2%)	
Not defined	16,310 (23.8%)	180 (15.2%)	138 (18.5%)	994 (13.8%)	14,998 (25.3%)		7,693 (22.4%)	8,617 (25.2%)	
Size of Polyp (mm)						4.2×10^{-3}			$2.1 \times 10^{-?}$
<10	29,686 (43.3%)	608 (51.4%)	348 (46.6%)	3,552 (49.2%)	25,178 (42.4%)		15,068 (44.0%)	14,618 (42.7%)	
≥10	7,199 (10.5%)	112 (9.5%)	88 (11.8%)	779 (10.8%)	6,220 (10.5%)		3,392 (9.9%)	3,807 (11.1%)	
Not defined	31,595 (46.1%)	462 (39.1%)	310 (41.6%)	2,882 (40.0%)	27,941 (47.1%)		15,808 (46.1%)	15,787 (46.1%)	
Adenoma Type						0.096			$3.2 \times 10^{-?}$
High Risk	15,983 (23.3%)	250 (21.2%)	190 (25.5%)	1,723 (23.9%)	13,820 (23.3%)		7,715 (22.5%)	8,268 (24.2%)	
Low Risk	52,497 (76.7%)	932 (78.8%)	556 (74.5%)	5,490 (76.1%)	45,519 (76.7%)		26,553 (77.5%)	25,944 (75.8%)	
Recurrence Status						7.9×10^{-2}			1.1×10^{-1}
Not Recurrence	49,030 (71.6%)	898 (76.0%)	623 (83.5%)	5,418 (75.1%)	42,091 (70.9%)		25,071 (73.2%)	23,959 (70.0%)	
Recurrence	19,450 (28.4%)	284 (24.0%)	123 (16.5%)	1,795 (24.9%)	17,248 (29.1%)		9,197 (26.8%)	10,253 (30.0%)	

n (%); Mean ± SD. [2]Pearson's Chi-squared test was used to calculate p-values for comparisons of categorical variables between groups

Table 2: Results of Polyp Recurrence associated with Demographic Variables: 5-Year Survival Analysis

Variable	Not Recurrence	Recurrence	p-value[2]	Adjusted Hazard Ratio*		
	N = 49,046[1]	N = 19,450[1]		HR[3]	95% CI[4]	p-value
Demographic Characteristics[5]						
Gender			$1.1 \times 10^{\square 1 \square}$			
Female	25,071 (73.2%)	9,197 (26.8%)		—	—	
Male	23,959 (70.0%)	10,253 (30.0%)		1.12	1.08, 1.17	$3.49 \times 10^{\square\square}$
Ethnicity			$7.9 \times 10^{\square 2 \square}$			
Non-Hispanic White	42,091 (70.9%)	17,248 (29.1%)		—	—	
Asian or Pacific Islander	898 (76.0%)	284 (24.0%)		0.75	0.63, 0.89	$1.24 \times 10^{\square 3}$
Hispanic	623 (83.5%)	123 (16.5%)		0.91	0.72, 1.15	$4.32 \times 10^{\square 1}$
Non-Hispanic Black	5,418 (75.1%)	1,795 (24.9%)		0.87	0.81, 0.93	$2.92 \times 10^{\square\square}$
Obesity[6]	15,752 (69.0%)	7,090 (31.0%)	$2.6 \times 10^{\square 2 \square}$	1.14	1.09, 1.18	$5.32 \times 10^{\square 1 \square}$
Polyp Onset Age (yr)[7]			$8.1 \times 10^{\square 1 \square\square}$			
≤50	13,466 (72.6%)	5,085 (27.4%)		0.87	0.80, 0.95	$8.90 \times 10^{\square\square}$
51-75	32,615 (70.0%)	13,948 (30.0%)		–	-	–
≥ 76	2,949 (87.6%)	417 (12.4%)		0.73	0.65, 0.83	$4.78 \times 10^{\square\square}$

[1]n (%); [2]Pearson's Chi-squared test; [3]HR = Hazard Ratio, [4]CI = Confidence Interval.

Model adjustments: [5]adjusted for age group; [6]adjusted for sex, age group and race/ethnicity; [7] adjusted for sex, obesity, race/ethnicity, Non-steroidal anti-inflammatory drugs (NSAIDs) and Aspirin use

Table 3: Results of Polyp Characteristics Associated with Recurrence: 5-Year Survival Analysis

Variable	Not Recurrence	Recurrence	p-value[2]	Adjusted Hazard Ratio*		
	N = 49,046[1]	N = 19,450[1]		HR[3]	95% CI[4]	p-value
Polyp Characteristics[5]						
Polyp Type			3.3×10^{-22}			
Tubular	12,687 (71.8%)	4,979 (28.2%)		—	—	
Mixed	11,318 (68.8%)	5,137 (31.2%)		1.36	1.29, 1.43	3.41×10^{-3}
Non-neoplastic	6,959 (79.0%)	1,854 (21.0%)		0.59	0.54, 0.64	1.58×10^{-3}
Not defined	13,787 (73.5%)	4,963 (26.5%)		0.51	0.47, 0.56	$4.31 \times 10^{\square\square\square}$
Serrated	1,974 (71.9%)	770 (28.1%)		1.31	1.19, 1.45	$5.42 \times 10^{\square\square}$
Tubulovillous	1,584 (67.4%)	765 (32.6%)		2.15	1.96, 2.36	$1.40 \times 10^{\square\square\square}$
Villous	721 (42.3%)	982 (57.7%)		2.40	2.18, 2.65	$5.26 \times 10^{\square\square\square}$
Dysplasia			0.11			
Low grade	48,237 (71.6%)	19,102 (28.4%)		—	—	
High grade	793 (69.5%)	348 (30.5%)		2.91	2.59, 3.27	$7.06 \times 10^{\square\square 2}$
Number of Polyp			$1.1 \times 10^{\square 31}$			
<3	32,059 (73.1%)	11,808 (26.9%)		—	—	
≥3	5,618 (67.7%)	2,685 (32.3%)		1.70	1.62, 1.79	$2.53 \times$

				HR	CI	
						$10^{\square\square\square}$
Not defined	11,353 (69.6%)	4,957 (30.4%)		1.17	1.09, 1.27	$4.94 \times 10^{\square\square}$
Size of Polyp (mm)			$8.6 \times 10^{\square\square}$			
<10	21,215 (71.5%)	8,471 (28.5%)		—	—	
≥10	5,034 (69.9%)	2,165 (30.1%)		1.65	1.56, 1.75	$2.15 \times 10^{\square\square 3}$
Not defined	22,781 (72.1%)	8,814 (27.9%)		0.81	0.77, 0.85	$8.77 \times 10^{\square^1\square}$
Adenoma Type			$7.5 \times 10^{\square\square\square}$			
High Risk	10,636 (66.5%)	5,347 (33.5%)		2.75	2.64, 2.86	$2.2 \times 10^{\square 16}$
Low Risk	38,394 (73.1%)	14,103 (26.9%)		—	—	

[1]n (%); [2]Pearson's Chi-squared test; [3]HR = Hazard Ratio, [4]CI = Confidence Interval.

[5]adjusted for sex, age group, race/ethnicity, polyp onset age (yrs), obesity, Non-steroidal anti-inflammatory drugs (NSAIDs) and Aspirin use.

Figure Legends:

Figure 1: Patient Selection and Cohort Characteristics for the Vanderbilt Polypectomy Cohort. (A): Flowchart illustrating the inclusion and exclusion criteria for patients undergoing colonoscopy and polypectomy from 1990 to July 2024, resulting in a final cohort of 68,480 patients. (B): Stratification of the polypectomy cohort by demographic factors (ethnicity and sex) and clinical variables (adenoma risk, histology, obesity, and age at polyp onset).

Figure 2: Adjusted Survival Curves for Time to Polyp Recurrence After Polypectomy in the Vanderbilt Polypectomy Cohort. (A) Survival by polyp type. (B) Survival by dysplasia grade. (C) Survival by number of polyps. (D) Survival by polyp size (mm). The reference group for polyp type is Tubular; for dysplasia, Low grade; for number of polyps, <3; and for polyp size, <10 mm. *P*-values are derived from adjusted Cox proportional hazards models. HR, hazard ratio; CI, confidence interval.

 Total Patients (1990 – July 2024) leveraging resources of EHR at VUMC (>3.5 million patients)

- History of Polyp
- Family History of CRC/Polyp
- Hematochezia
- Melena/Occult GI Bleeding

- Altered Bowel Motility
- Diarrhea/Constipation
- Iron Deficiency Anemia
- Abdominal Pain
- ICD-9/ICD-10/HCPCS Codes

Patient Included after Initial Screening (n = 807,590) → **No Colonoscopy (n = 669,344)**

Colonoscopy (n = 138,246) → **No Polyp Identified (n = 7,086)**

Polyp Suspicion (n = 131,160) → **Non-Interventional Colonoscopy (n = 54,496)**

Polypectomy (n = 76,664) → **Excluded (n = 8,184)**
Quality Control Review;
Missing Report:
Selection Criteria (≥18 years age);
loss of follow-up; death

Histopathological Confirmed Polyp (n = 68,480)

(A)

Polypectomy Cohort (n = 68,480)

Racial and Gender Disparity

Ethnicity
- White
- Black
- Asian/Pacific Islander
- Hispanic

Gender
- Male
- Female

Clinical Variables

Adenoma Stratification
- High Risk
- Low Risk

Histology Stratification
- Polyp Size
- Polyp Number
- Polyp Types

Obesity

Polyp Onset Age Stratification (y)
- Early Onset (0-50 y)
- Mid Onset (51-75 y)
- Late Onset (≥ 76 y)

(B)

(A) Polyp Type

	HR	95% CI	p-value
Villous	2.4	2.18, 2.65	5.26×10^{-70}
Tubulovillous	2.15	1.96, 2.36	1.4×10^{-59}
Serrated	1.31	1.19, 1.45	5.42×10^{-8}
Not defined	0.51	0.47, 0.56	4.31×10^{-59}
Non-neoplastic	0.59	0.54, 0.64	1.58×10^{-38}
Mixed	1.36	1.29, 1.43	3.41×10^{-30}

(B) Dysplasia

	HR	95% CI	p-value
High grade	2.91	2.59, 3.27	7.06×10^{-72}

(C) Number of Polyps

	HR	95% CI	p-value
≥3	1.70	1.62, 1.79	2.53×10^{-88}
Unknown	1.17	1.09, 1.27	4.94×10^{-5}

(D) Polyp Size (mm)

	HR	95% CI	p-value
≥10	1.65	1.56, 1.75	2.15×10^{-63}
Unknown	0.81	0.77, 0.85	8.77×10^{-18}